A Detailed Analysis of Perforations During Chronic Total Occlusion Angioplasty.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
14 10 2019
Historique:
received: 08 03 2019
revised: 25 04 2019
accepted: 07 05 2019
pubmed: 1 7 2019
medline: 15 9 2020
entrez: 1 7 2019
Statut: ppublish

Résumé

This study sought to describe the angiographic characteristics, strategy associated with perforation, and the management of perforation during chronic total occlusion percutaneous coronary intervention (CTO PCI). The incidence of perforation is higher during CTO PCI compared with non-CTO PCI and is reportedly highest among retrograde procedures. Among 1,000 consecutive patients who underwent CTO PCI in a 12-center registry, 89 (8.9%) had core lab-adjudicated angiographic perforations. Clinical perforation was defined as any perforation requiring treatment. Major adverse cardiac events (MAEs) were defined as in-hospital death, cardiac tamponade, and pericardial effusion. Among the 89 perforations, 43 (48.3%) were clinically significant, and 46 (51.7%) were simply observed. MAE occurred in 25 (28.0%), and in-hospital death occurred in 9 (10.1%). Compared with nonclinical perforations, clinical perforations were larger in size, more often at a collateral location, had a high-risk shape, and less likely to cause staining or fast filling. Compared with perforations not associated with MAE, perforations associated with MAE were larger in size, more proximal or at collateral location, and had a high-risk shape. When the core lab attributed the perforation to the approach used when the perforation occurred, 61% of retrograde perforations by other classifications were actually antegrade. Larger size, proximal or collateral location, and high-risk shapes of a coronary perforation were associated with MAE. Six of 10 perforations occurred with antegrade approaches among patients who had both strategies attempted. These finding will help emerging CTO operators understand high-risk features of the perforation that require treatment and inform future comparisons of retrograde and antegrade complications.

Sections du résumé

OBJECTIVES
This study sought to describe the angiographic characteristics, strategy associated with perforation, and the management of perforation during chronic total occlusion percutaneous coronary intervention (CTO PCI).
BACKGROUND
The incidence of perforation is higher during CTO PCI compared with non-CTO PCI and is reportedly highest among retrograde procedures.
METHODS
Among 1,000 consecutive patients who underwent CTO PCI in a 12-center registry, 89 (8.9%) had core lab-adjudicated angiographic perforations. Clinical perforation was defined as any perforation requiring treatment. Major adverse cardiac events (MAEs) were defined as in-hospital death, cardiac tamponade, and pericardial effusion.
RESULTS
Among the 89 perforations, 43 (48.3%) were clinically significant, and 46 (51.7%) were simply observed. MAE occurred in 25 (28.0%), and in-hospital death occurred in 9 (10.1%). Compared with nonclinical perforations, clinical perforations were larger in size, more often at a collateral location, had a high-risk shape, and less likely to cause staining or fast filling. Compared with perforations not associated with MAE, perforations associated with MAE were larger in size, more proximal or at collateral location, and had a high-risk shape. When the core lab attributed the perforation to the approach used when the perforation occurred, 61% of retrograde perforations by other classifications were actually antegrade.
CONCLUSIONS
Larger size, proximal or collateral location, and high-risk shapes of a coronary perforation were associated with MAE. Six of 10 perforations occurred with antegrade approaches among patients who had both strategies attempted. These finding will help emerging CTO operators understand high-risk features of the perforation that require treatment and inform future comparisons of retrograde and antegrade complications.

Identifiants

pubmed: 31255554
pii: S1936-8798(19)31164-1
doi: 10.1016/j.jcin.2019.05.024
pii:
doi:

Types de publication

Comparative Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1902-1912

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Taishi Hirai (T)

Saint Luke's Mid America Heart Institute, Kansas City, Missouri; Department of Medicine, Division of Cardiology, University of Missouri Kansas City, Kansas City, Missouri.

William J Nicholson (WJ)

York Hospital, York, Pennsylvania.

James Sapontis (J)

Monash Heart, Melbourne, Australia.

Adam C Salisbury (AC)

Saint Luke's Mid America Heart Institute, Kansas City, Missouri; Department of Medicine, Division of Cardiology, University of Missouri Kansas City, Kansas City, Missouri.

Steven P Marso (SP)

Research Medical Center, Kansas City, Missouri.

William Lombardi (W)

University of Washington, Seattle, Washington.

Dimitri Karmpaliotis (D)

Columbia University, New York Presbyterian Hospital, New York, New York.

Jeffrey Moses (J)

Columbia University, New York Presbyterian Hospital, New York, New York.

Ashish Pershad (A)

Banner University Medical Center, Phoenix, Arizona.

R Michael Wyman (RM)

Torrance Medical Center, Torrance, California.

Anthony Spaedy (A)

Boone County Hospital, Columbia, Missouri.

Stephen Cook (S)

Peacehealth Sacred Heart Medical Center, Springfield, Oregon.

Parag Doshi (P)

Alexian Brothers Medical Center, Chicago, Illinois.

Robert Federici (R)

Presbyterian Health System, Albuquerque, New Mexico.

Karen Nugent (K)

Saint Luke's Mid America Heart Institute, Kansas City, Missouri.

Kensey L Gosch (KL)

Saint Luke's Mid America Heart Institute, Kansas City, Missouri.

John A Spertus (JA)

Saint Luke's Mid America Heart Institute, Kansas City, Missouri; Department of Medicine, Division of Cardiology, University of Missouri Kansas City, Kansas City, Missouri.

J Aaron Grantham (JA)

Saint Luke's Mid America Heart Institute, Kansas City, Missouri; Department of Medicine, Division of Cardiology, University of Missouri Kansas City, Kansas City, Missouri. Electronic address: jgrantham@saint-lukes.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH